Effect of gemcitabine in enhancing the radiosensitivity of HepG2 hepatoma cells and the possible mechanism.
- Author:
Zhi-hai LING
1
;
Quan-quan SUN
;
Yao-wei ZHANG
;
Jian GUAN
;
Yi DING
;
Long-hua CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; drug effects; Cell Cycle Checkpoints; drug effects; Deoxycytidine; analogs & derivatives; pharmacology; Hep G2 Cells; Humans; Radiation Tolerance; drug effects; Radiation-Sensitizing Agents; pharmacology
- From: Journal of Southern Medical University 2011;31(12):1993-1996
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of gemcitabine in enhancing the radiosensitivity of hepatoma cell line HepG2 and explore its mechanisms.
METHODSClonogenic survival assay is employed to calculate the ratios of L-Q model radiation biology parameters and radiosensitization after different doses of irradiation. Flow cytometry was used to detect the changes in HepG2 cell cycle and apoptosis rate after gemcitabine treatment and radiation exposure.
RESULTSThe survival fraction at 2 Gy of HepG2 cells treated with gemcitabine was significantly lower, and the value of alpha was significantly higher than those of untreated cells. GEM treatment increased the percentage of radiation-induced G0/G1 phase cells and cell apoptosis.
CONCLUSIONGemcitabine can significantly enhance the radiosensitivity of HepG2 cells by enhancing radiation-induced cell cycle arrest in G0/G1 phase and cell apoptosis.
